Drug developer Can-Fite BioPharma Ltd. (TASE:CFBI) today reported that the Phase I/II clinical trial of its liver cancer treatment CF102 found a sharp and continued reduction in the hepatitis C virus in one patient who suffered from both diseases. The finding was found in blood tests conducted by a World Heath Organization-certified laboratory.
Can-Fite CEO Prof. Pnina Fishman said, "The results are a breakthrough in treating hepatitis patients. The combination of a drug that is effective in lowering the virus together with an impressive safety profile, opens a huge potential market for the company for this drug. It should be remembered that the hepatitis C virus is a major factor in the development of severe liver diseases, including cirrhosis and liver cancer, and restricting the virus will help in the prevention and treatment of these diseases.
Can-Fite's share price rose 10.6% in morning trading to NIS 0.58, giving a market cap of NIS 126 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 30, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010